Lane 1: Melanoma tissue lysate
Lane 2: B18F1 cell lysate
Recombinant Rabbit monoclonal primary
MelanA Recombinant Rabbit Monoclonal Antibody [SC56-02] (ET1610-47)
Melanoma tissue lysate, B18F1 cell lysate, human melanoma tissue, B16F1.
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A affinity purified.
Antigen LB39 AA antibody; Antigen LB39-AA antibody; Antigen SK29 AA antibody; Antigen SK29-AA antibody; MAR1_HUMAN antibody; MART 1 antibody; MART-1 antibody; MART1 antibody; Melan A antibody; Melan A protein antibody; Melanoma antigen recognized by T cells 1 antibody; Melanoma antigen recognized by T-cells 1 antibody; MLAN A antibody; MLANA antibody; OTTHUMP00000021036 antibody; OTTHUMP00000021037 antibody; OTTHUMP00000021038 antibody; Protein Melan-A antibody
Expression is restricted to melanoma and melanocyte cell lines and retina.
Golgi apparatus, trans-Golgi network membrane, Endoplasmic reticulum membrane, Melanosome.
Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.